全球III期ALEX研究更新疗效与安全性数据及EML4-ALK融合变异对阿来替尼治疗未经治疗ALK阳性晚期非小细胞肺癌疗效的影响
ALEX研究更新随访10个月后,阿来替尼组研究者评估的中位无进展生存期为34.8个月,克唑替尼组为10.9个月(分层HR=0.43,95%CI 0.32-0.58)。EML4-ALK变异1、2、3a/b不影响无进展生存期、客观缓解率或缓解持续时间,各变异亚组中阿来替尼均优于克唑替尼。
要点
- 阿来替尼组中位无进展生存期34.8个月,克唑替尼组10.9个月,分层HR=0.43(95%CI 0.32-0.58)。
- EML4-ALK变异1、2、3a/b不影响无进展生存期、客观缓解率或缓解持续时间。
- 血浆和组织中各EML4-ALK变异亚组中,阿来替尼的无进展生存期均长于克唑替尼。
核心结论
- 在未经治疗的ALK阳性晚期非小细胞肺癌中,阿来替尼研究者评估的无进展生存期持续优于克唑替尼,且不受EML4-ALK变异影响。
研究设计与样本
- 全球III期ALEX研究,患者随机接受阿来替尼600 mg每日两次或克唑替尼250 mg每日两次,直至疾病进展、毒性、死亡或退出。
- 本次更新分析基于额外10个月随访,数据截止日期为2017年12月1日;此前数据截止日期为2017年2月9日。
- 采用杂交捕获二代测序检测基线与治疗前血浆和组织生物标志物样本以确定EML4-ALK变异。
主要发现
- 研究者评估的无进展生存期阿来替尼组优于克唑替尼组,分层风险比=0.43(95%置信区间:0.32-0.58)。
- 中位无进展生存期阿来替尼组为34.8个月,克唑替尼组为10.9个月。
- 129例患者血浆样本和124例组织样本中可检测到EML4-ALK融合;变异1、2和3a/b不影响无进展生存期、客观缓解率或缓解持续时间。
- 在血浆和组织中,EML4-ALK变异1、2和3a/b各亚组内,阿来替尼的研究者评估无进展生存期均长于克唑替尼。
- 尽管阿来替尼治疗持续时间更长(阿来替尼组27.0个月 vs 克唑替尼组10.8个月),阿来替尼的安全性仍优于克唑替尼。
局限性
- EML4-ALK变异分析为探索性亚组分析。
- EML4-ALK变异对治疗获益的影响基于回顾性分析提示。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: At the prior data cutoff (February 9, 2017) the ALEX trial showed superior investigator-assessed progression-free survival (PFS) for alectinib versus crizotinib in untreated, anaplastic lymphoma kinase (ALK)-positive, advanced NSCLC (hazard ratio = 0.47, 95% confidence interval: 0.34-0.65, p < 0.001). The median PFS in the alectinib arm was not reached versus 11.1 months with crizotinib. Retrospective analyses suggest that the echinoderm microtubule-associated protein-like 4 gene-ALK variant (EML4-ALK) may influence ALK-inhibitor treatment benefit. We present updated analyses, including exploratory subgroup analysis by EML4-ALK variant, after an additional 10 months' follow-up (cutoff December 1, 2017). METHODS: Patients were randomized to receive twice-daily alectinib, 600 mg, or crizotinib, 250 mg, until disease progression, toxicity, death, or withdrawal. PFS was determined by the investigators. Baseline plasma and tissue biomarker samples were analyzed by using hybrid-capture, next-generation sequencing to determine EML4-ALK variant. RESULTS: Baseline characteristics were balanced. Investigator-assessed PFS was prolonged with alectinib (stratified hazard ratio = 0.43, 95% confidence interval: 0.32-0.58). The median PFS times were 34.8 months with alectinib and 10.9 months with crizotinib. EML4-ALK fusions were detectable in 129 patient plasma samples and 124 tissue samples; variants 1, 2, and 3/ab did not affect PFS, objective response rate, or duration of response. Investigator-assessed PFS was longer for alectinib than for crizotinib across EML4-ALK variants 1, 2, and 3a/b in plasma and tissue. Despite longer treatment duration (27.0 months in the case of alectinib versus 10.8 months in the case of crizotinib), the safety of alectinib compared favorably with that of crizotinib. CONCLUSION: Alectinib continues to demonstrate superior investigator-assessed PFS versus crizotinib in untreated ALK-positive NSCLC, irrespective of EML4-ALK variant.
引用
- Camidge DR, Dziadziuszko R, Peters S, et al. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. J Thorac Oncol. 2019. PMID: 30902613. doi:10.1016/j.jtho.2019.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。